CD70: An emerging target in cancer immunotherapy

Pharmacology and Therapeutics

Volumn 155, Issue , 2015, Pages 1-10

  Jacobs, J ^a,b   Deschoolmeester, V ^a,b   Zwaenepoel, K ^b   Rolfo, C ^b   Silence, K ^c   Rottey, S ^d   Lardon, F ^a   Smits, E ^a   Pauwels, P ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c Rogers BVBA   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cancer immunotherapy; CD27; CD70; Combination therapy

Indexed keywords

AMG 172; ARGX 110; CD27 ANTIGEN; CD70 ANTIBODY; CD70 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; DOCETAXEL; DOXORUBICIN; EVEROLIMUS; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANZYME B; INTERLEUKIN 15; INTERLEUKIN 2; MITOXANTRONE; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PD 1 ANTIBODY; PEPTIDE VACCINE; PERFORIN; SGN CD 70 A; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARLILUMAB; VORSETUZUMAB MAFODOTIN; CD70 PROTEIN, HUMAN;

ANOREXIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY-DEPENDENT CELLULAR PHAGOCYTOSIS; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPHOCYTE DEPLETION; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MYOEPITHELIAL CARCINOMA; MYOEPITHELIOMA; NEPHROTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEINURIA; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TREATMENT RESPONSE; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

ANIMALS; ANTIGENS, CD70; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84945441052     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.07.007     Document Type: Review

References (102)

1. P.J. Adam, J.A. Terrett, G. Steers, L. Stockwin, J.A. Loader, G.C. Fletcher, and et al. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding Br J Cancer 95 3 2006 298 306 10.1038/sj.bjc.6603222
2. A. Agathanggelou, G. Niedobitek, R. Chen, J. Nicholls, W. Yin, and L.S. Young Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells Am J Pathol 147 4 1995 1152 1160
3. K. Agematsu, S. Hokibara, H. Nagumo, K. Shinozaki, S. Yamada, and A. Komiyama Plasma cell generation from B-lymphocytes via CD27/CD70 interaction Leuk Lymphoma 35 3-4 1999 219 225 10.3109/10428199909145724
4. S. Aggarwal, T. He, W. Fitzhugh, K. Rosenthal, B. Feild, J. Heidbrink, and et al. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer Gynecol Oncol 115 3 2009 430 437 10.1016/j.ygyno.2009.08.031
5. R. Arens, K. Schepers, M.A. Nolte, M.F. van Oosterwijk, R.A. van Lier, T.N. Schumacher, and et al. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation J Exp Med 199 11 2004 1595 1605 10.1084/jem.20031111
6. S. Aulwurm, J. Wischhusen, M. Friese, J. Borst, and M. Weller Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo Int J Cancer 118 7 2006 1728 1735 10.1002/ijc.21544
7. A. Awada, C. Rolfo, S. Rottey, L. Ysebrant de Lendonck, W. Schroyens, F. Offner, and et al. A Phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in solid and hematologic malignancies Presented at ASCO Annual Meeting 2014 J Clin Oncol 32 2014 5s (Suppl.; abstr 3023)
8. S.P. Bak, M.S. Barnkob, A. Bai, E.M. Higham, K.D. Wittrup, and J. Chen Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells J Immunol 189 4 2012 1708 1716 10.4049/jimmunol.1201271
9. P. Bertrand, C. Maingonnat, D. Penther, S. Guney, P. Ruminy, J.M. Picquenot, and et al. The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma Genes Chromosomes Cancer 52 8 2013 764 774 10.1002/gcc.22072
10. J. Borst, J. Hendriks, and Y. Xiao CD27 and CD70 in T cell and B cell activation Curr Opin Immunol 17 3 2005 275 281 10.1016/j.coi.2005.04.004
11. T.E. Boursalian, J.A. McEarchern, C.L. Law, and I.S. Grewal Targeting CD70 for human therapeutic use Adv Exp Med Biol 647 2009 108 119 10.1007/978-0-387-89520-8-7
12. M.K. Callahan, M.A. Postow, and J.D. Wolchok CTLA-4 and PD-1 pathway blockade: Combinations in the clinic Front Oncol 4 2014 385 10.3389/fonc.2014.00385
13. A. Chahlavi, P. Rayman, A.L. Richmond, K. Biswas, R. Zhang, M. Vogelbaum, and et al. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70 Cancer Res 65 12 2005 5428 5438 10.1158/0008-5472.can-04-4395
14. G. Chen, and L.A. Emens Chemoimmunotherapy: Reengineering tumor immunity Cancer Immunol Immunother 62 2 2013 203 216 10.1007/s00262-012-1388-0
15. C. Claus, C. Riether, C. Schurch, M.S. Matter, T. Hilmenyuk, and A.F. Ochsenbein CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth Cancer Res 72 14 2012 3664 3676 10.1158/0008-5472.can-11-2791
16. J.M. Coquet, J.C. Ribot, N. Babala, S. Middendorp, G. van der Horst, Y. Xiao, and et al. Epithelial and dendritic cells in the thymic medulla promote CD4+Foxp3+ regulatory T cell development via the CD27-CD70 pathway J Exp Med 210 4 2013 715 728 10.1084/jem.20112061
17. B. Couderc, L. Zitvogel, V. Douin-Echinard, L. Djennane, H. Tahara, G. Favre, and et al. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells Cancer Gene Ther 5 3 1998 163 175
18. J. Couzin-Frankel Breakthrough of the year 2013. Cancer immunotherapy Science 342 6165 2013 1432 1433 10.1126/science.342.6165.1432
19. V. De Colvenaer, S. Taveirne, J. Hamann, A.M. de Bruin, M. De Smedt, T. Taghon, and et al. Continuous CD27 triggering in vivo strongly reduces NK cell numbers Eur J Immunol 40 4 2010 1107 1117 10.1002/eji.200939251
20. V.E.S. Deschoolmeester, M. Peeters, and J.B. Vermorken Status of active specific immunotherapy for stage II, stage III, and resected stage IV colon cancer Curr Colorectal Cancer Rep 9 2013 10
21. J. Diegmann, K. Junker, B. Gerstmayer, A. Bosio, W. Hindermann, J. Rosenhahn, and et al. Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry Eur J Cancer 41 12 2005 1794 1801 10.1016/j.ejca.2005.05.005
22. J. Diegmann, K. Junker, I.F. Loncarevic, S. Michel, B. Schimmel, and F. von Eggeling Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes Neoplasia 8 11 2006 933 938 10.1593/neo.06451
23. J. Font, L. Pallares, J. Martorell, E. Martinez, A. Gaya, J. Vives, and et al. Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus Clin Immunol Immunopathol 81 3 1996 239 243
24. F. Ghiringhelli, and L. Apetoh The interplay between the immune system and chemotherapy: Emerging methods for optimizing therapy Expert Rev Clin Immunol 10 1 2014 19 30 10.1586/1744666x.2014.865520
25. L. Glouchkova, B. Ackermann, A. Zibert, R. Meisel, M. Siepermann, G.E. Janka-Schaub, and et al. The CD70/CD27 pathway is critical for stimulation of an effective cytotoxic T cell response against B cell precursor acute lymphoblastic leukemia J Immunol 182 1 2009 718 725
26. N. Goto, H. Tsurumi, M. Takemura, N. Kanemura, S. Kasahara, T. Hara, and et al. Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone Leuk Lymphoma 53 8 2012 1494 1500 10.3109/10428194.2012.660627
27. H.J. Gruss, and M.E. Kadin Pathophysiology of Hodgkin's disease: Functional and molecular aspects Baillieres Clin Haematol 9 3 1996 417 446
28. B.K. Han, A.M. White, K.H. Dao, D.R. Karp, E.K. Wakeland, and L.S. Davis Increased prevalence of activated CD70+CD4+ T cells in the periphery of patients with systemic lupus erythematosus Lupus 14 8 2005 598 606
29. J. Hendriks, L.A. Gravestein, K. Tesselaar, R.A. van Lier, T.N. Schumacher, and J. Borst CD27 is required for generation and long-term maintenance of T cell immunity Nat Immunol 1 5 2000 433 440 10.1038/80877
30. J. Hendriks, Y. Xiao, and J. Borst CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool J Exp Med 198 9 2003 1369 1380 10.1084/jem.20030916
31. R.Q. Hintzen, R. de Jong, C.E. Hack, M. Chamuleau, E.F. de Vries, I.J. ten Berge, and et al. A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex J Immunol 147 1 1991 29 35
32. R.Q. Hintzen, S.M. Lens, M.P. Beckmann, R.G. Goodwin, D. Lynch, and R.A. van Lier Characterization of the human CD27 ligand, a novel member of the TNF gene family J Immunol 152 4 1994 1762 1773
33. T. Hishima, M. Fukayama, Y. Hayashi, T. Fujii, T. Ooba, N. Funata, and et al. CD70 expression in thymic carcinoma Am J Surg Pathol 24 5 2000 742 746
34. A.W. Ho, E. Hatjiharissi, B.T. Ciccarelli, A.R. Branagan, Z.R. Hunter, X. Leleu, and et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia Blood 112 12 2008 4683 4689 10.1182/blood-2007-04-084525
35. S. Hori, T. Nomura, and S. Sakaguchi Control of regulatory T cell development by the transcription factor Foxp3 Science 299 5609 2003 1057 1061 10.1126/science.1079490
36. J. Huang, C. Jochems, A.M. Anderson, T. Talaie, A. Jales, R.A. Madan, and et al. Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity J Immunol 190 12 2013 6250 6258 10.4049/jimmunol.1300022
37. B.F. Israel, M. Gulley, S. Elmore, S. Ferrini, W.H. Feng, and S.C. Kenney Anti-CD70 antibodies: A potential treatment for EBV+ CD70-expressing lymphomas Mol Cancer Ther 4 12 2005 2037 2044 10.1158/1535-7163.mct-05-0253
38. J. Jacobs, K. Zwaenepoel, P. Aftimos, C. Rolfo, S. Rottey, L. Ysebrant de Lendonck, and et al. CD70 (TNFSF7), a receptor involved in acute immune modulation of viral infection, is frequently overexpressed in solid and haematological malignancies Poster session presented at 26th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics. Barcelona 2014
39. J. Jacobs, K. Zwaenepoel, C. Rolfo, J. Van den Bossche, K. Silence, C. Hermans, and et al. Unlocking the potential of CD70 as an interesting immunotherapeutic target for non-small cell lung cancer Oncotarget 6 15 2015 13462 13475
40. S. Jacquot, T. Kobata, S. Iwata, C. Morimoto, and S.F. Schlossman CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: Enhancement of plasma cell differentiation by CD27 signaling J Immunol 159 6 1997 2652 2657
41. M. Jak, R. Mous, E.B. Remmerswaal, R. Spijker, A. Jaspers, A. Yague, and et al. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia Leuk Lymphoma 50 5 2009 788 801 10.1080/10428190902803677
42. S.C. Jeffrey, P.J. Burke, R.P. Lyon, D.W. Meyer, D. Sussman, M. Anderson, and et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology Bioconjug Chem 24 7 2013 1256 1263 10.1021/bc400217g
43. L.B. Jilaveanu, J. Sznol, S.A. Aziz, D. Duchen, H.M. Kluger, and R.L. Camp CD70 expression patterns in renal cell carcinoma Hum Pathol 43 9 2012 1394 1399 10.1016/j.humpath.2011.10.014
44. K. Junker, W. Hindermann, F. von Eggeling, J. Diegmann, K. Haessler, and J. Schubert CD70: A new tumor specific biomarker for renal cell carcinoma J Urol 173 6 2005 2150 2153 10.1097/01.ju.0000158121.49085.ba
45. K. Kato, P. Chu, S. Takahashi, H. Hamada, and T.J. Kipps Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells Exp Hematol 35 3 2007 434 442 10.1016/j.exphem.2006.10.018
46. A.M. Keller, T.A. Groothuis, E.A. Veraar, M. Marsman, Maillette de Buy, L. Wenniger, and et al. Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules Proc Natl Acad Sci U S A 104 14 2007 5989 5994 10.1073/pnas.0700946104
47. J.M. Kelly, P.K. Darcy, J.L. Markby, D.I. Godfrey, K. Takeda, H. Yagita, and et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection Nat Immunol 3 1 2002 83 90 10.1038/ni746
48. M. Kuka, I. Munitic, M.L. Giardino Torchia, and J.D. Ashwell CD70 is downregulated by interaction with CD27 J Immunol 191 5 2013 2282 2289 10.4049/jimmunol.1300868
49. A. Laouar, V. Haridas, D. Vargas, X. Zhinan, D. Chaplin, R. Van Lier, and et al. CD70+ antigen-presenting cell controls the expansion and differentiation of T cells in the intestinal mucosa Nat Immunol 6 7 2005 8
50. C.L. Law, K.A. Gordon, B.E. Toki, A.K. Yamane, M.A. Hering, C.G. Cerveny, and et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates Cancer Res 66 4 2006 2328 2337 10.1158/0008-5472.can-05-2883
51. W.W. Lee, Z.Z. Yang, G. Li, C.M. Weyand, and J.J. Goronzy Unchecked CD70 expression on T cells lowers threshold for T cell activation in rheumatoid arthritis J Immunol 179 4 2007 2609 2615
52. S.M. Lens, P. Drillenburg, B.F. den Drijver, G. van Schijndel, S.T. Pals, R.A. van Lier, and et al. Aberrant expression and reverse signalling of CD70 on malignant B cells Br J Haematol 106 2 1999 491 503
53. S.M. Lens, K. Tesselaar, M.H. van Oers, and R.A. van Lier Control of lymphocyte function through CD27-CD70 interactions Semin Immunol 10 6 1998 491 499 10.1006/smim.1998.0154
54. T. Lindgren, T. Stigbrand, K. Riklund, L. Johansson, and D. Eriksson Gene expression profiling in MOLT-4 cells during gamma-radiation-induced apoptosis Tumour Biol 33 3 2012 689 700 10.1007/s13277-012-0329-z
55. N. Liu, X. Sheng, Y. Liu, X. Zhang, and J. Yu Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas OncoTargets Ther 6 2013 615 619 10.2147/ott.s44445
56. W.A. Loenen, E. De Vries, L.A. Gravestein, R.Q. Hintzen, R.A. Van Lier, and J. Borst The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis Eur J Immunol 22 2 1992 447 455 10.1002/eji.1830220224
57. A.F. Lopez, D.J. Williamson, J.R. Gamble, C.G. Begley, J.M. Harlan, S.J. Klebanoff, and et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival J Clin Invest 78 5 1986 1220 1228 10.1172/jci112705
58. M.G. Lorenz, J.A. Kantor, J. Schlom, and J.W. Hodge Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L) Hum Gene Ther 10 7 1999 1095 1103 10.1089/10430349950018094
59. D.G. Mack, A.M. Lanham, B.E. Palmer, L.A. Maier, and A.P. Fontenot CD27 expression on CD4+ T cells differentiates effector from regulatory T cell subsets in the lung J Immunol 182 11 2009 7317 7324 10.4049/jimmunol.0804305
60. M. Maerevoet ARGX-110, a novel monoclonal antibody targeting CD70, is associated with biological activity in patients with relapsed/refractory T-cell lymphomas Presented at ICML 13th international conference on malignant lymphoma 2015
61. M. Matter, S. Mumprecht, D.D. Pinschewer, V. Pavelic, H. Yagita, S. Krautwald, and et al. Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL Eur J Immunol 35 11 2005 3229 3239 10.1002/eji.200535179
62. M. Matter, B. Odermatt, H. Yagita, J.M. Nuoffer, and A.F. Ochsenbein Elimination of chronic viral infection by blocking CD27 signaling J Exp Med 203 9 2006 2145 2155 10.1084/jem.20060651
63. J.A. McEarchern, L.M. Smith, C.F. McDonagh, K. Klussman, K.A. Gordon, C.A. Morris-Tilden, and et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70 Clin Cancer Res 14 23 2008 7763 7772 10.1158/1078-0432.ccr-08-0493
64. D. Miura, K. Yoneyama, Y. Furuhata, and K. Shimizu Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer J Nippon Med Sch 81 4 2014 211 220
65. I. Munitic, M. Kuka, A. Allam, J.P. Scoville, and J.D. Ashwell CD70 deficiency impairs effector CD8 T cell generation and viral clearance but is dispensable for the recall response to lymphocytic choriomeningitis virus J Immunol 190 3 2013 1169 1179 10.4049/jimmunol.1202353
66. L. Nelson, W.F. Jumbe, Sonal Patel, Benny Amore, Marc Retter, and Vincent Chow Translating preclinical PK/PD tumor volume modeling data to predict AMG172 PK and dose-escalation scheme in FIH. [abstract] Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR 10.1158/1538-7445.AM2013-3359 Cancer Res 73 2013 (8 Suppl:Abstract nr 3359)
67. A. Nilsson, A. de Milito, F. Mowafi, G. Winberg, O. Bjork, E.Z. Wolpert, and et al. Expression of CD27-CD70 on early B cell progenitors in the bone marrow: Implication for diagnosis and therapy of childhood ALL Exp Hematol 33 12 2005 1500 1507 10.1016/j.exphem.2005.10.005
68. A. Nolte, R.W. van Olffen, K. van Gisbergen, and R. van Lier Timing and tuning of CD27-CD70 interactions: The impact of signal strength in setting the balance between adaptive responses and immunopathology Immunol Rev 229 2009 15
69. K. Oelke, Q. Lu, D. Richardson, A. Wu, C. Deng, S. Hanash, and et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors Arthritis Rheum 50 6 2004 1850 1860 10.1002/art.20255
70. C. Petrau, M. Cornic, P. Bertrand, C. Maingonnat, V. Marchand, J.M. Picquenot, and et al. CD70: A potential target in breast cancer? J Cancer 5 9 2014 761 764 10.7150/jca.10360
71. K.V. Prasad, Z. Ao, Y. Yoon, M.X. Wu, M. Rizk, S. Jacquot, and et al. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein Proc Natl Acad Sci U S A 94 12 1997 6346 6351
72. G.A. Rabinovich, D. Gabrilovich, and E.M. Sotomayor Immunosuppressive strategies that are mediated by tumor cells Annu Rev Immunol 25 2007 267 296 10.1146/annurev.immunol.25.022106.141609
73. C. Riether, C. Schurch, and A.F. Ochsenbein Modulating CD27 signaling to treat cancer Oncoimmunology 1 9 2012 1604 1606 10.4161/onci.21425
74. D.J. Roberts, N.A. Franklin, L.M. Kingeter, H. Yagita, A.L. Tutt, M.J. Glennie, and et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells J Immunother 33 8 2010 769 779 10.1097/CJI.0b013e3181ee238f
75. C. Rolfo, G. Sortino, E. Smits, F. Passiglia, G. Bronte, M. Castiglia, and et al. Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer? Expert Rev Anticancer Ther 14 10 2014 1173 1187 10.1586/14737140.2014.952287
76. M.C. Ryan, H. Kostner, K.A. Gordon, S. Duniho, M.K. Sutherland, C. Yu, and et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75 Br J Cancer 103 5 2010 676 684 10.1038/sj.bjc.6605816
77. Sharsti Sandall, Martha Anderson, Mechthild Jonas, Albina Nesterova, Jamie Miyamoto, Ivan J. Stone, and et al. Abstract 2647: SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL) Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA 2014
78. D.R. Shaffer, A.M. Sheehan, Z. Yi, C.C. Rodgers, C.M. Bollard, M.K. Brenner, and et al. Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection Pediatr Blood Cancer 59 4 2012 758 761 10.1002/pbc.23352
79. V. Shahabi, M.A. Postow, D. Tuck, and J.D. Wolchok Immune-priming of the tumor microenvironment by radiotherapy: Rationale for combination with immunotherapy to improve anticancer efficacy Am J Clin Oncol 38 1 2015 90 97 10.1097/COC.0b013e3182868ec8
80. K. Silence, T. Dreier, M. Moshir, P. Ulrichts, S.M. Gabriels, M. Saunders, and et al. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade MAbs 6 2 2014 523 532 10.4161/mabs.27398
81. K. Soukup, and X. Wang Radiation meets immunotherapy - A perfect match in the era of combination therapy? Int J Radiat Biol 1-15 2015 10.3109/09553002.2014.995383
82. T. Tadmor, and A. Polliack Elevated soluble CD 27 levels (TNF-receptor) may predict survival in diffuse large B-cell lymphoma - Revisiting "the super-family" saga Leuk Lymphoma 53 8 2012 1439 1440 10.3109/10428194.2012.666546
83. N.M. Tannir, A. Forero-Torres, R. Ramchandren, S.K. Pal, S.M. Ansell, J.R. Infante, and et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma Invest New Drugs 2014 10.1007/s10637-014-0151-0
84. K. Tesselaar, R. Arens, G.M. van Schijndel, P.A. Baars, M.A. van der Valk, J. Borst, and et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions Nat Immunol 4 1 2003 49 54 10.1038/ni869
85. L.J. Thomas, L.Z. He, H. Marsh, and T. Keler Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity Oncoimmunology 3 1 2014 e27255 10.4161/onci.27255
86. J.M. Van den Bergh, V.F. Van Tendeloo, and E.L. Smits Interleukin-15: New kid on the block for antitumor combination therapy Cytokine Growth Factor Rev 2014 10.1016/j.cytogfr.2014.09.001
87. R. van Doorn, R. Dijkman, M.H. Vermeer, J.J. Out-Luiting, E.M. van der Raaij-Helmer, R. Willemze, and et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis Cancer Res 64 16 2004 5578 5586 10.1158/0008-5472.can-04-1253
88. R.E. Vatner, B.T. Cooper, C. Vanpouille-Box, S. Demaria, and S.C. Formenti Combinations of immunotherapy and radiation in cancer therapy Front Oncol 4 2014 325 10.3389/fonc.2014.00325
89. M.T. Vossen, M. Matmati, K.M. Hertoghs, P.A. Baars, M.R. Gent, G. Leclercq, and et al. CD27 defines phenotypically and functionally different human NK cell subsets J Immunol 180 6 2008 3739 3745
90. Q.J. Wang, K. Hanada, P.F. Robbins, Y.F. Li, and J.C. Yang Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma Cancer Res 72 23 2012 6119 6129 10.1158/0008-5472.CAN-12-0588
91. W. Wang, S. Qin, and L. Zhao Docetaxel enhances CD3+ CD56+ cytokine-induced killer cells-mediated killing through inducing tumor cells phenotype modulation Biomed Pharmacother 69 2015 18 23 10.1016/j.biopha.2014.10.026
92. D. Widney, G. Gundapp, J.W. Said, M. van der Meijden, B. Bonavida, A. Demidem, and et al. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma Clin Immunol 93 2 1999 114 123 10.1006/clim.1999.4782
93. J. Wischhusen, G. Jung, I. Radovanovic, C. Beier, J.P. Steinbach, A. Rimner, and et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma Cancer Res 62 9 2002 2592 2599
94. Y. Xiao, J. Hendriks, P. Langerak, H. Jacobs, and J. Borst CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation J Immunol 172 12 2004 7432 7441
95. Z.Z. Yang, D.M. Grote, B. Xiu, S.C. Ziesmer, T.L. Price-Troska, L.S. Hodge, and et al. TGF-beta upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma Leukemia 28 9 2014 1872 1884 10.1038/leu.2014.84
96. Z.Z. Yang, A.J. Novak, M.J. Stenson, T.E. Witzig, and S.M. Ansell Intratumoral CD4+ CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma Blood 107 9 2006 3639 3646 10.1182/blood-2005-08-3376
97. Z.Z. Yang, A.J. Novak, S.C. Ziesmer, T.E. Witzig, and S.M. Ansell CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+ CD25 T cells Blood 110 7 2007 2537 2544 10.1182/blood-2007-03-082578
98. Y. Yoshimoto, Y. Suzuki, K. Mimura, K. Ando, T. Oike, H. Sato, and et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model PLoS One 9 3 2014 e92572 10.1371/journal.pone.0092572
99. P. Yu, Y. Lee, W. Liu, T. Krausz, A. Chong, H. Schreiber, and et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors J Exp Med 201 5 2005 779 791 10.1084/jem.20041684
100. S.E. Yu, S.H. Park, and Y.K. Jang Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during progression to breast cancer Mol Cells 29 2 2010 217 221 10.1007/s10059-010-0052-9
101. Y. Zhou, X. Liu, L. Xu, H. Tseng, Y. Cao, J. Jiang, and et al. Matrix metalloproteinase-8 is overexpressed in Waldenstrom's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27 Clin Lymphoma Myeloma Leuk 11 1 2011 172 175 10.3816/CLML.2011.n.041
102. Y. Zhou, X. Qiu, Y. Luo, J. Yuan, Y. Li, Q. Zhong, and et al. Histone modifications and methyl-CpG-binding domain protein levels at the TNFSF7 (CD70) promoter in SLE CD4+ T cells Lupus 20 13 2011 1365 1371 10.1177/0961203311413412